Technical Analysis for ARNA - Arena Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
F 61.2 -0.42% -0.26
ARNA closed up 1.62 percent on Friday, May 14, 2021, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical ARNA trend table...

Date Alert Name Type % Chg
New Downtrend Bearish -0.42%
Slingshot Bearish Bearish Swing Setup -0.42%
Lower Bollinger Band Walk Weakness -0.42%
Oversold Stochastic Weakness -0.42%
Lower Bollinger Band Walk Weakness 1.19%
Multiple of Ten Bullish Other 1.19%
Below Lower BB Weakness 1.19%
Down 3 Days in a Row Weakness 1.19%
Down 4 Days in a Row Weakness 1.19%
Lower Bollinger Band Touch Weakness 1.19%
Older End-of-Day Signals for ARNA ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 2 % about 2 hours ago
Slingshot Bearish Entry about 2 hours ago
Fell Below Previous Day's Low about 2 hours ago
Lower Bollinger Band Support about 2 hours ago
Down 1% about 3 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Arena Pharmaceuticals, Inc. Description

Arena Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company offers BELVIQ, a drug candidate approved by the United States food and drug administration for chronic weight management in adults. It is also involved in the development of APD811, an agonist of the prostacyclin receptor, which is in Phase I clinical trials for the treatment of pulmonary arterial hypertension; and temanogrel, an inverse agonist of the serotonin 2A receptor that is in Phase I clinical trials for the treatment of thrombotic diseases. In addition, the company's preclinical development products comprise APD334, an agonist of the S1P1 receptor intended for the treatment of autoimmune diseases; APD371, an agonist of the cannabinoid receptor 2 intended for the treatment of pain; and GPR119 agonists intended for the treatment of type 2 diabetes. Further, it manufactures drug products under a manufacturing services agreement. The company has a marketing and supply agreement with Ildong Pharmaceutical Co., Ltd. for the commercialization of BELVIQ in South Korea. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Clinical Development Pain Diabetes Medication Autoimmune Diseases Pharmacology Autoimmune Disease Hypertension Pulmonary Arterial Hypertension Metabolic Disease Drug Product Metabolic Diseases Drug Products Treatment Of Autoimmune Disease Treatment Of Autoimmune Diseases Cannabinoid Weight Management Cannabinoids Inflammatory United States Food And Drug Administration Agonist Manufacturing Services Agreement Prostacyclin

Is ARNA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 90.19
52 Week Low 51.41
Average Volume 419,956
200-Day Moving Average 72.53
50-Day Moving Average 68.68
20-Day Moving Average 65.39
10-Day Moving Average 63.17
Average True Range 2.61
ADX 26.15
+DI 10.50
-DI 25.98
Chandelier Exit (Long, 3 ATRs ) 62.10
Chandelier Exit (Short, 3 ATRs ) 67.38
Upper Bollinger Band 70.65
Lower Bollinger Band 60.12
Percent B (%b) 0.13
BandWidth 16.10
MACD Line -2.05
MACD Signal Line -1.69
MACD Histogram -0.3671
Fundamentals Value
Market Cap 3.57 Billion
Num Shares 58.2 Million
EPS 10.84
Price-to-Earnings (P/E) Ratio 5.67
Price-to-Sales 1055.65
Price-to-Book 3.25
PEG Ratio 0.46
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 64.66
Resistance 3 (R3) 64.61 63.49 64.12
Resistance 2 (R2) 63.49 62.68 63.52 63.94
Resistance 1 (R1) 62.48 62.18 62.99 62.53 63.77
Pivot Point 61.36 61.36 61.62 61.39 61.36
Support 1 (S1) 60.35 60.55 60.86 60.40 59.15
Support 2 (S2) 59.23 60.05 59.26 58.98
Support 3 (S3) 58.22 59.23 58.80
Support 4 (S4) 58.27